Gangjian Qin, MD

Gangjian QinAssociate Professor in Medicine-Cardiology and Molecular Pharmacology and Biological Chemistry
312-695-4965

See this investigators faculty profile for publications and other professional information.

Ganjian Qin received an MD degree at the Tongji Medical University in China. His residency training was completed at the Union Hospital of Tongji Medical University, Department of Pediatrics (1989–91). At Union Hospital he also completed a pediatric fellowship with a specialization in neonatology (1991–92). He completed a fellowship in molecular and cellular biology at the International Centre for Genetic Engineering and Biotechnology, Trieste, Italy (1995–98). He worked as a research specialist in hematology and oncology at the University of Illinois at Chicago (1998–2001) and as senior research fellow at Caritas St. Elizabeth’s Medical Center, Tufts University School of Medicine (2001–04).

Dr. Qin served on the faculty of Tongji Medical University from 1992–95 and at Tufts University School of Medicine from 2004–07.

He was assistant professor of medicine, molecular pharmacology and biological chemistry at Northwestern University's Feinberg School of Medicine from 2007–2011. In 2012, he was appointed associate professor, and he is an investigator in the Feinberg Cardiovascular Research Institute.

Dr. Qin’s research program is dedicated to defining the molecular mechanisms that support cardiovascular biology and contribute to the recovery from cardiovascular disease, and to translating the results from these basic science investigations to clinical applications. A portion of his research focuses on the transcriptional networks and genetic pathways that control the growth and function of blood vessels under both physiological and pathological conditions, with particular attention devoted to the involvement of the E2F transcription factors in ischemic angiogenesis and blood pressure regulation. He is also committed to improving the effectiveness of stem- and progenitor-cell therapy for the treatment of ischemic disease by characterizing the molecular interactions between various stem-cell populations (e.g., bone-marrow derived stem/progenitor cells, cardiac progenitor cells) and their microenvironment, and by investigating the genetic and epigenetic mechanisms that govern the differentiation of embryonic and induced-pluripotent stem (ES and iPS) cells.

 A novel 2-step procedure to expand clonogenic

Publications

See this investigators faculty profile for publications and other professional information.